Postmenopausal Osteoporosis Drugs Market to Grow at 4.02% CAGR Driven by Emergence of Novel Agents to 2020
PUNE, India, May 23, 2016 /PRNewswire-iReach/ -- A trend to watch in the postmenopausal osteoporosis drugs market is the emergence of novel agents. There have been encouraging developments in the postmenopausal osteoporosis drug pipeline. Novel agents may offer superior benefit-risk profiles and improved safety profiles compared with conventional treatment options. Many drugs have obtained approval while others are in different phases of development. For instance, drugs such as odanacatib (MK-0822) by Merck exert their pharmacological action by inhibiting the enzyme cathepsin K, which is primarily responsible for the degradation of the bone matrix by osteoclasts.
(Photo - http://photos.prnewswire.com/prnh/20160523/370655)
Complete report on postmenopausal osteoporosis drugs market spread across 60 pages, analyzing 4 major companies and providing 35 data exhibits are now available at http://www.rnrmarketresearch.com/global-postmenopausal-osteoporosis-drugs-market-2016-2020-market-report.html
According to the 2016 report, a key growth driver for postmenopausal osteoporosis drugs market is the growing prevalence of postmenopausal osteoporosis. The average life expectancy for women is estimated to be around 73 years, which increases the risk of developing postmenopausal osteoporosis. During menopause, the amount of estrogen in the body declines, resulting in osteoporosis. According to the World Health Organization (WHO), osteoporosis is second only to cardiovascular disease as a global healthcare problem. It is estimated that over 200 million people worldwide have this disease, and this number is increasing considerably. It is estimated that 30% of all the women in the postmenopausal stage have postmenopausal osteoporosis in the US and Europe.
Global Postmenopausal Osteoporosis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. This report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. This report covers the present scenario and the growth prospects of the Global Postmenopausal Osteoporosis Drugs Market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded and generic drugs used to treat and prevent postmenopausal osteoporosis. Order a copy of Global Postmenopausal Osteoporosis Drugs Market 2016-2020 report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=545105
Key players in the global postmenopausal osteoporosis drugs market: Eli Lilly, Amgen, Merck, and Novartis.
Other prominent vendors in the market are: Allergan, Amgen Astellas Biopharm, Deltanoid Pharmaceuticals, Noven, Novo Nordisk, Osteologix, Pfizer, PhytoHealth, Radius Health, Tarsa Therapeutics, UCB, Uni-Bio Science Group, Upsher-Smith Laboratories, Watson Pharmaceuticals, and Zosano Pharma.
About Postmenopausal Osteoporosis Drugs Market
Bones have the ability to grow and heal naturally, but changes in diet, exercise levels, and body chemistry lead to changes in the bone mineral density. This results in osteoporosis, which is characterized by low bone density and structural deterioration of bone tissues, leading to fragile bones. Rapid bone resorption or slow bone replacement can result in the development of the disease. Gender, age, body size (low body weight), ethnicity, and family history also play a role in developing osteoporosis. Other risk factors include medication, calcium and vitamin intake, alcohol intake, and smoking.
Women are at a greater risk of developing osteoporosis than men as estrogens play an important role in maintaining bone strength. Small amounts of bone are lost as part of normal aging process, but on reaching menopause, estrogen levels decline drastically, leading to a greater risk of developing osteoporosis.
Further, the postmenopausal osteoporosis drugs market report states that one challenge that could hinder market growth is the low diagnosis rate of postmenopausal osteoporosis. Referred to as a silent disease the patient remains unaware of it until it has progressed to the higher stages.
Explore other new reports on Osteoporosis Drugs Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/diseases-treatment/osteoporosis-drugs
Another related report is Global Osteoporosis Drugs Market 2015-2019, the analysts forecast global osteoporosis drugs market to grow at a CAGR of 4.14% over the period 2014-2019. Promoting bone health awareness is important to help reduce the rate and risk of osteoporosis. Increased awareness among patients and physicians will lead to early disease diagnosis and treatment. This will also lead to better acceptability of osteoporosis drugs, thus increasing the drug penetration. The rise in the general awareness about osteoporosis has led to an increase in research funding and support for clinical and support services. Continued advances in risk assessment, screening, prevention, and treatment offer unique opportunities to improve bone health. Browse complete report @ http://www.rnrmarketresearch.com/global-osteoporosis-drugs-market-2015-2019-market-report.html
Key players in global osteoporosis drugs market: Amgen, Eli Lilly, Merck and Novartis
Other prominent vendors in the market are: Abiogen Pharma, Deltanoid Pharmaceuticals, F. Hoffmann La Roche, GlaxoSmithKline, IMMD, Ligand Pharmaceuticals, NPS Pharma, Pantarhei Bioscience, Pfizer, PhytoHealth, Radius Health, UPSHER-SMITH LABORATORIES and Zosano Pharma
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Media Contact: Ritesh Tiwari, RnRMarketResearch, + 1 888 391 5441, firstname.lastname@example.org
News distributed by PR Newswire iReach: https://ireach.prnewswire.com